Anti-TFPI antibodies are used in the immunodetection of the protein tissue factor pathway inhibitor. In humans, the canonical protein has a reported length of 304 amino acid residues and a mass of 35 kDa. It has been described to be a secreted protein. Up to 2 different isoforms have been reported for this protein. It is notably widely expressed in many tissue types. TFPI is reported to inhibit factor X (X(a)) directly and, in a Xa-dependent way, inhibits VIIa/tissue factor activity, presumably by forming a quaternary Xa/LACI/VIIa/TF complex. Post-translational modifications have been described, including O-glycosylation.
The TFPI marker can be used to identify Lymphatic Vessel Endothelial Cells.* Synonyms for this target antigen include LACI, TFI, TFPI1, anti-convertin, extrinsic pathway inhibitor, and EPI. TFPI gene orthologs have been reported in the mouse, rat, bovine, chimpanzee and chicken species. A number of TFPI antibodies have been mentioned in research publications and have associated citations. ELISA is a widely used application for these antibodies. In addition, Western Blot is also a common application.
*HuBMAP Human Reference Atlas v1.4